Remove 2026 Remove Dosage Remove Drug Development
article thumbnail

Biopharmaceutical bioseparation systems market to value $20bn

European Pharmaceutical Review

billion by 2026, achieving a compound annual growth rate (CAGR) of 13.2 Advancements are underway in terms of product developments and innovations, with significant emphasis being placed on optimising and streamlining existing methods. percent CAGR between 2022 and 2026.

Dosage 111
article thumbnail

Top 20 Radiopharma Companies Based on Market Cap

PharmaShots

threshold by 2026. This year, Novartis has secured the top position with a market cap of $207.65B, followed by Bayer and Lantheus Medical Imaging PharmaShots has compiled a list of the Top 20 Radiopharma Companies developing products as a treatment option, ranked based on their market cap.

Dosage 56